NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market on Friday that the US Food and Drug Administration has cleared for marketing its therascreen KRAS RGQ PCR Kit to be sold as a companion diagnostic test for Erbitux (cetuximab), a drug used for treating colorectal cancer.

Erbitux is an EGFR inhibitor marketed in the US by Bristol-Myers Squibb along with Eli Lily and its Imclone Systems unit. Outside of the US and Canada, it is sold by Germany's Merck KGaA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.